Second part of Belopenem formulation work is initiated
Double Bond Pharmaceutical has now initiated the second part of formulation work for Belopenem project. In this part the targeting effect of a number of formulation that passed all the analytical criteria in part one will be tested in vivo and the best one will be further selected and developed as a new medicine. Belopenem is a combination of meropenem, which is a well-known antibiotic against pneumonia, and DBP’s own platform Belogal® that targets the active substance to the selected organ, in this very case to the lung. “We are very satisfied with being able to keep the timeline and